Nifty 50Healthcarenifty 50
Cipla Share Price & Analysis
Cipla is a leading Indian pharmaceutical company with strengths in respiratory, HIV, and chronic therapies.
Live price
CIPLA · Healthcare
₹1,350.00
−5.00 (−0.37%)
Day High
₹1,372.70
Day Low
₹1,319.00
52W High
₹1,593.30
52W Low
₹1,165.70
Volume today: 40.78 L
Key fundamentals
Market cap
₹1.2 L Cr
P/E ratio
28.0x
P/B ratio
3.8x
ROE
14.5%
Debt / Equity
—
Dividend yield
0.8%
Revenue growth
—
Earnings growth
—
Live fundamentals from Yahoo Finance where available. Reference ratios may lag the latest quarterly results.
PaisaTamil Consensus
HOLDScore 52/100 · Low confidence
Mixed signals across valuation and momentum. Existing investors may hold; new entries should wait for clarity.
12M Price Target
₹1,391
Low ₹1,229 · High ₹1,593
Analyst-style Breakdown
Strong Buy
0
Buy
0
Hold
13
Sell
0
Strong Sell
0
Derived from public market signals — price momentum, earnings trend, valuation, quality, and technical position — modelled in an analyst-style consensus format.
Signal Breakdown
Price Momentum30/100
1M -2.4%, 1Y -14.0%
Earnings Trend50/100
Latest quarter revenue ₹7.4k Cr, profit ₹878 Cr
Valuation75/100
P/E 28.0x vs sector median ~35x
Financial Quality65/100
ROE 14.5%, ROCE 13.2%
Technical Position48/100
Trading between 52W low 1166 and high 1593
Modelled from public market signals — not live broker analyst data. For education only; not SEBI-registered investment advice.
Price Chart
Quarterly Results
| Quarter | Revenue | Net Profit | EPS | Rev YoY | Profit YoY |
|---|---|---|---|---|---|
| Sept 2026 | ₹7.4k Cr | ₹878 Cr | ₹10.86 | +7.8% | -32.4% |
| Jun 2026 | ₹7.1k Cr | ₹789 Cr | ₹9.77 | — | — |
| Mar 2026 | ₹6.5k Cr | ₹555 Cr | ₹6.87 | — | — |
| Dec 2025 | ₹7.0k Cr | ₹676 Cr | ₹8.37 | — | — |
| Jun 2025 | ₹6.8k Cr | ₹1.3k Cr | ₹16.07 | — | — |
Reference Ratios
Market Capⓘ
₹1.2 L Cr
P/E Ratioⓘ
28.0x
P/B Ratioⓘ
3.8x
ROEⓘ
14.5%
ROCEⓘ
13.2%
Div Yieldⓘ
0.8%
Company Overview
Cipla manufactures generic drugs for India and export markets, with a growing US inhaler and complex generics portfolio.
Strengths
- + Strong India chronic therapy franchise
- + Respiratory product leadership
- + US complex generics pipeline
- + Consistent cash generation
Risks
- − US price erosion in generics
- − FDA compliance requirements
- − Competition in respiratory segment
- − Currency impact on exports
Latest News
No recent news articles for Cipla yet. Check back after the next hourly scan.
Browse all market news →Investor Questions
Yes. Cipla is a current constituent of the Nifty 50, which means it is among the 50 largest and most liquid stocks on the National Stock Exchange (NSE).